+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Pyrogen Testing Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 4591716
  • Report
  • May 2020
  • Region: Global
  • 115 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • BioMerieux
  • Ellab A/S
  • Genscript
  • Lonza Group
  • Merck Kgaa
  • Wako Chemicals Usa, Inc.
  • MORE
The pyrogen testing market is expected to register a growth rate of nearly 12.5% during the forecast period. This report is segmented by product, test type, application, and geography. The market is primarily driven by increased demand for pyrogenic testing products in the pharmaceutical and biotechnology industry and rising investments in research and development. The presence of well-developed healthcare infrastructure, and well-defined rules and regulations for pharmaceutical manufacturing process should help North America to dominate the market share in the forecast period.

Chronic disease prevalence is high in developed countries and is growing at a high rate in emerging markets. Thus, the demand for pyrogen testing along with increasing awareness is expected to result in high growth during the forecast period.

Other factors driving this market are high investments in research and development in the life science industry, the rise in the number of pharmaceutical and biotechnological companies and rise in the launch of biologic products and surge in new innovative drugs.

Key Market Trends

Monocyte Activation Test is Expected to Witness Highest Growth Rate

The measurement of pyrogens is an essential safety measure for pharmaceutical products with parenteral administration and for medical devices. The Monocyte Activation Test (MAT) is used to detect or quantify substances that activate human monocytes or monocytic cells to release endogenous mediators which have a role in the human fever response. Alternatives to Rabbit Pyrogen Test were developed taking into account the fever induction mechanism of pyrogen-induced cytokines. The monocyte activation test (MAT), for example, is based on the detection of IL-6 or IL-1b induced in human blood monocytes or monocytic cell lines stimulated in vitro by pyrogens. It has been suggested by the Brazilian Journal of Pharmaceutical Science that the Monocyte Activation Test is getting more attention in the pharmaceutical industry which in turn is contributing to the rapid growth of the same.

North America is Expected to Dominate the Market in Forecast Period

The North America is expected to dominate the market share with well-established healthcare infrastructure, better regulatory framework, and government support and presence of many large biotechnological and biopharmaceutical firms, such as Merck, Lonza Group, among others. These companies have a high focus on new drug and biologics development with continuous support from the government in the form of funding from several government bodies and investors, which fuel the growth of this market. The Asia Pacific is expected to exhibit the highest growth rate. The healthy CAGR is expected due to rising healthcare expenditure in countries, such as India, China, and Japan.

Competitive Landscape

The market for pyrogen testing is moderately competitive and is dominated by a few major players, such as Merck KGaA, Lonza Group, BioMérieux, and GenScript. Rising innovations in have promoted the entry of novel players who are also entering the market and throwing competition to gain the market share.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown
2 of 4


  • BioMerieux
  • Ellab A/S
  • Genscript
  • Lonza Group
  • Merck Kgaa
  • Wako Chemicals Usa, Inc.
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rapid Growth in Pharmaceutical and Biotechnology Industries
4.2.2 Rising R&D Expenditure in Life Science
4.3 Market Restraints
4.3.1 Stringent Government Regulations
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product
5.1.1 Kits and Reagents
5.1.2 Services
5.1.3 Instruments
5.2 By Test Type
5.2.1 LAL Tests Chromogenic Tests Turbidimetric Tests Gel Clot Tests
5.2.2 Rabbit Pyrogen Test
5.2.3 Monocyte Activation Test
5.2.4 Other Test Types
5.3 By End User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Medical Device Companies
5.3.3 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Associates of Cape Cod, Inc.
6.1.2 BioMerieux
6.1.3 Charles River Laboratories, Inc.
6.1.4 Ellab A/S
6.1.5 Genscript
6.1.6 Lonza Group
6.1.7 Merck Kgaa
6.1.8 Thermo Fisher Scientific, Inc.
6.1.9 Wako Chemicals Usa, Inc.
6.1.10 WUXI Pharmatech (Cayman) Inc.

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Associates of Cape Cod, Inc.
  • BioMerieux
  • Charles River Laboratories, Inc.
  • Ellab A/S
  • Genscript
  • Lonza Group
  • Merck Kgaa
  • Thermo Fisher Scientific, Inc.
  • Wako Chemicals Usa, Inc.
  • WUXI Pharmatech (Cayman) Inc.
Note: Product cover images may vary from those shown